A new report from The King’s Fund, NHS and Life Sciences Industry Partnerships: Collaborating to Improve Care, shows how working together can help the NHS improve care. The NHS is under pressure, and joining forces with the life sciences sector could bring in new ideas, tools, and support.
In the fast-paced world of medical and regulatory affairs, large pharmaceutical companies are under increasing pressure to stay ahead. PharmaMedic Consultancy (PMC) understands this need and offers a flexible, expert-driven solution. With a network of over 100 consultants, PMC provides specialised, outsourced expertise that integrates seamlessly with your team to handle crucial tasks—from launch planning and KOL (Key Opinion Leader) engagement to regulatory compliance and certification.
Cancer immunotherapy represents a remarkable advancement in medical science, offering hope for conditions once considered untreatable. While some patients experience life-changing results, a large number face limited success or significant side effects. This is particularly evident with melanoma treatments, where fewer than half of patients benefit from immunotherapy.
The global demand for generic pharmaceuticals is growing, but manufacturers face significant hurdles. Regulatory complexity, market entry barriers, and the need for product differentiation require strategic thinking. At the same time, manufacturers must maintain tight control over costs to succeed.
In PMC's first breakfast briefing of 2024, PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson was joined by guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences to discuss machine learning and artificial intelligence, and a discussion on how this technology may impact our day-to-day roles.
Our next meeting on Wednesday, 24th April, 2024 will discuss machine learning and artificial intelligence and a discussion on how this technology may impact our day-to-day roles. Join Dr Malcolm Barratt-Johnson, Managing Director of PharmaMedic Consultancy and our guest speaker Dr Christine Grew, Director of Regulatory Affairs at Canopy Life Sciences.
Among the measures unveiled in the UK government’s Autumn Statement, published on 17 November 2022, Chancellor of the Exchequer Jeremy Hunt said that there will be regulatory reform to encourage economic growth in key industries, including the life sciences.
Pharmacovigilance (PV) – the proactive maintenance of drug safety through collection, detection, assessment, monitoring and prevention of adverse effects – has been evolving since the first concerns were raised over the negative effects of chloroform anaesthetic in the 1800s. Today, it is just as important that pharma, start-ups and regulators keep up to date with the latest trends to ensure that drugs are safe and monitoring practices remain fit for purpose.
Wellcome has awarded £1.8m to the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) so that they can investigate and produce guidance on regulation of digital mental health tools.
The National Institute for Health and Care Excellence (NICE) plans to speed up its processes for evaluating lower-risk treatments using a lighter touch approach. This will free up time to consider the increasing number of more complex applications. NICE states that this method will make its assessments faster, enabling quicker access to promising new treatments.
